Safety and outcomes of percutaneous tracheostomy in coronavirus disease 2019 pneumonitis patients requiring prolonged mechanical ventilation

A Takhar1, C Tornari1, N Amin1, D Wyncoll2, S Tricklebank2, A Arora1, I Ahmad3, R Simo1 and P Surda1

Departments of 1Otolaryngology and Head and Neck Surgery, 2Critical Care and 3Anaesthesia, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, London, UK

Abstract

Objectives. Tracheostomy for coronavirus disease 2019 pneumonitis patients requiring prolonged invasive mechanical ventilation remains a matter of debate. This study analysed the timing and outcomes of percutaneous tracheostomy, and reports our experience of a dedicated ENT–anaesthetics department led tracheostomy team.

Method. A prospective single-centre observational study was conducted of patients undergoing tracheostomy, who had been diagnosed with coronavirus disease 2019 pneumonitis, between 21st March and 20th May 2020.

Results. Eighty-one patients underwent tracheostomy after a median (interquartile range) of 16 (13–20) days of invasive mechanical ventilation. Median follow-up duration was 32 (23–40) days. Of patients, 86.7 per cent were successfully liberated from invasive mechanical ventilation in a median (interquartile range) of 12 (7–16) days. Moreover, 68.7 per cent were subsequently discharged from hospital. On univariate analysis, there was no difference in outcomes between early (before day 14) and late (day 14 or later) tracheostomy. The mortality rate was 8.6 per cent and no deaths were tracheostomy related.

Conclusion. Outcomes appear favourable when patients are carefully selected. Percutaneous tracheostomy performed via a multidisciplinary approach, with appropriate training, was safe and optimised healthcare resource utilisation.

Introduction

Tracheostomy for weaning critically ill patients with coronavirus disease 2019 (Covid-19) who are receiving invasive mechanical ventilation remains a matter of debate. Controversy exists regarding timing, outcomes, prognosis, techniques to reduce aerosol generation and risk of transmission to healthcare workers. The mortality rate for those critically ill with Covid-19 pneumonitis is higher than for non-coronavirus disease viral pneumonia (50.7 per cent vs 22.0 per cent), as described in the Intensive Care National Audit and Research Centre (‘ICNARC’) report.1 For those patients who survive, the median duration of requirement for ventilation is reported at between 20 and 27 days.2,3

It is likely that a significant number of these patients may benefit from tracheostomy, as it has a recognised role in non-coronavirus disease populations to facilitate ventilatory weaning. These include reductions in: incidence of ventilator-associated pneumonia, duration of sedation, duration of mechanical ventilation and length of stay in critical care.3,4 Timing of tracheostomy insertion remains controversial, with no survival benefit demonstrated with earlier tracheostomy insertion.5

In the context of Covid-19, ENT-UK currently recommends performing tracheostomy on or after 14 days of endotracheal intubation.6 Additionally, the British Laryngological Association advises deferring tracheostomy until the patient has a positive end-expiratory pressure (PEEP) requirement of 10 cmH2O or less and a fraction of inspired oxygen of 0.4 or less.7 More recently, an international consensus guideline has recommended waiting at least 10 days, and only considering tracheostomy when the patient is showing signs of clinical improvement.8 Furthermore, a high incidence of thromboembolism has been reported in critically ill Covid-19 patients, necessitating therapeutic anticoagulation. These factors collectively pose significant peri-operative risks of hypoxia, de-recruitment and bleeding.

There has been understandable concern regarding the risk to healthcare workers when performing tracheostomy, which is mainly based upon evidence from the severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) pandemic.10 Current published evidence does not suggest a difference between surgical tracheostomy and percutaneous tracheostomy with regard to aerosol generation or outcomes,11–13 and whilst most have recognised this equipoise, some experts have published recommendations favouring a percutaneous approach.14,15
Guy’s and St Thomas’ NHS Foundation Trust was one of the first centres in the UK to treat Covid-19 patients, and hence make decisions about tracheostomy. In March 2020, because of an anticipated surge in demand, we developed a dedicated ENT–anaesthetics department led tracheostomy team, through close collaboration with intensive care. Indications for tracheostomy were agreed, and intensive training and simulation was undertaken. The purpose was to rapidly up-skill our ENT clinicians to safely perform percutaneous procedures with appropriate modifications to minimise aerosol generation. Our initial protocol and recommendation are described in detail in our recent publication.16

This paper primarily aimed to analyse the intra-operative and post-tracheostomy outcomes in patients with Covid-19 pneumonitis requiring prolonged mechanical ventilation. In addition, we sought to analyse any effect of timing of tracheostomy upon outcomes in our cohort, and report our experience of both staff and patient safety.

Materials and methods

Study population and setting

This was a prospective observational cohort study of patients undergoing elective tracheostomy between 21st March and 20th May 2020 at Guy’s and St Thomas’ Hospital. All patients included were diagnosed with laboratory confirmed Covid-19; all were critically ill with acute hypoxemic respiratory failure and receiving invasive mechanical ventilation. The decision to perform tracheostomy for anticipated prolonged respiratory weaning was made jointly by two critical care consultants after evaluation of each patient’s clinical course and prognosis, considering the factors defined in our local guideline.16

By default, procedures were performed percutaneously at the bedside on the intensive care unit. In cases where there were potential contraindications to this approach (e.g. anatomical issues, a difficult upper airway, coagulopathy), a joint ENT–anaesthetics assessment was undertaken, including ultrasound of the neck, to determine the safest surgical approach and location (in which to undertake the tracheostomy) prior to proceeding.

The intensive care unit or dedicated ENT–anaesthetics tracheostomy team performed all procedures using the Traco® ‘percutan experc’ system according to a pre-agreed protocol (Figure 1). Patients were followed up until discharge from hospital or death.

This study was registered and approved with the institutional clinical governance department, and was approved as a service evaluation.

Study objectives and measurements

Electronic medical records were used to obtain patients’ baseline characteristics, including age, gender, ethnicity, body mass index (BMI), number of very severe co-morbidities. Acute Physiology and Chronic Health Evaluation II (‘APACHE II’) score, and lowest recorded partial pressure of oxygen: fraction of inspired oxygen ratio within 24 hours of intensive care unit admission. We compared our cohort to the Intensive Care National Audit and Research Centre cohort that underwent advanced respiratory support during their critical care admission.1

With respect to tracheostomy, we analysed procedure timing (days since endotracheal intubation) and levels of respiratory support on the morning of the procedure. The recorded parameters were: PEEP, fraction of inspired oxygen, partial pressure of oxygen: fraction of inspired oxygen ratio, and active treatment with extracorporeal membrane oxygenation. Positive end-expiratory pressure and fraction of inspired oxygen were measured against our local guideline of PEEP of 10 cmH2O or less and fraction of inspired oxygen of 0.5 or less. Measurements of PEEP, fraction of inspired oxygen, and partial pressure of oxygen: fraction of inspired oxygen ratio for patients receiving extracorporeal membrane oxygenation were censored from analysis, as these would not accurately represent respiratory function in this cohort.

The laboratory serum biomarker C-reactive protein (CRP) was recorded on the day of the procedure, given its potential prognostic value in Covid-19 cases.17,18 In addition, we collected factors related to multi-organ dysfunction, including the requirement for vasopressors and/or renal replacement therapy.

Data on surgical technique, location, anticoagulant status, and intra- and post-operative complications were collected. The personal protective equipment worn by team members was recorded. All team members involved were surveyed and asked to report Covid-19 symptoms. These results were included if symptoms occurred within 5–14 days after a procedure.

The primary outcome was duration of ventilation post-tracheostomy. The endpoint of ventilation was defined as the day when all mechanical ventilation (including bilevel positive airway pressure and continuous positive airway pressure) was stopped for at least 24 hours.

Outcomes were also recorded from the day of tracheostomy until the day when: sedation was stopped (i.e. when intravenous sedative infusions of propofol, fentanyl, alfentanil or midazolam were stopped for at least 24 hours); the patient was discharged from the intensive care unit; decannulation of tracheostomy occurred; the patient was discharged from hospital; or death occurred. Where outcomes data were unobtainable, patients were censored from outcomes analysis.

Statistical analysis

For univariate analysis of the effect of timing of tracheostomy, patients were divided into two groups according to current guidelines: early tracheostomy group – less than 14 days after endotracheal intubation; and late tracheostomy group – 14 days or more after endotracheal intubation.6,7

Baseline characteristics, respiratory support and inflammatory markers on the day of tracheostomy, and outcomes, were compared between early and late tracheostomy groups. A Kolmogorov test showed abnormal distribution, hence non-parametric tests were used. P-values of less than 0.05 were considered significant; these were calculated using the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables. Spearman’s test was used for correlation co-efficients. Statistical analysis was performed with SPSS version 20.0 software (IBM, Armonk, New York, USA).

Results

Baseline characteristics

A total of 263 patients were admitted to the intensive care unit for invasive mechanical ventilation between 3rd March and 5th May 2020; all had been diagnosed with laboratory confirmed Covid-19 and were critically ill with acute hypoxemic...
respiratory failure. Of the patients, 81 (30.8 per cent) underwent tracheostomy for prolonged respiratory weaning between 21st March and 20th May 2020.

The median (interquartile range) age of the 81 patients was 55 (46–61) years, with a male to female ratio of 2:1. Baseline demographics, which were compared to the Intensive Care
The median (interquartile range) duration of invasive mechanical ventilation prior to tracheostomy was 16 (13–20) days. Fifty-seven tracheostomies (70.4 per cent) were performed on or after day 14. The (median (interquartile range)) levels of respiratory support required on the day of tracheostomy were as follows: PEEP of 8 (6–10) cmH₂O, fraction of inspired oxygen of 0.35 (0.3–0.4), and partial pressure of oxygen: fraction of inspired oxygen ratio of 204.9 (171.2–249.0). Sixty-two patients (93.9 per cent) required PEEP of 10 cmH₂O or less and fraction of inspired oxygen of 0.5 or less. The highest PEEP and fraction of inspired oxygen requirements were 14 cmH₂O and 0.55 respectively.

The median (interquartile range) CRP was 116 (50–192) mg/l. Nineteen patients (23.5 per cent) were receiving vasopressors, 29 (23.5 per cent) were receiving renal replacement therapy and 15 (18.5 per cent) were on extracorporeal membrane oxygenation. The results are summarised in Table 2.

### Procedures, complications and staff safety

Seventy-six procedures (93.8 per cent) were performed as percutaneous tracheostomy, and the remainder via a hybrid or open technique. A total of 78 procedures (96.3 per cent) were

### Table 1. Baseline characteristics

| Characteristics | ICNARC cohort (n = 6395)* | Current study cohort | Univariate analysis (p-values) |
|-----------------|---------------------------|----------------------|------------------------------|
|                 | Overall (n = 81) | Early tracheostomy (n = 24) | Late tracheostomy (n = 57) |
| Age at admission (years) | | | |
| – Mean (SD) | 58.8 (12.0) | 52.9 (12.2) | 58.4 (11.8) | 50.6 (11.8) | NS |
| – Median (IQR) | 60 (52–67) | 55 (46–61) | 60 (54–64) | 52 (45–59) | NS |
| Sex (n (%)) | | | |
| – Female | 1767 (27.6) | 26 (32.1) | 9 (37.5) | 17 (29.8) | NS |
| – Male | 4626 (72.4) | 55 (67.9) | 15 (62.5) | 40 (70.1) | NS |
| Ethnicity (n (%)) | | | |
| – White | 3770 (64.7) | 35 (43.2) | 11 (45.8) | 24 (42.1) | NS |
| – Mixed | 102 (1.8) | 4 (4.9) | 0 (0.0) | 4 (7.0) | NS |
| – Asian | 920 (15.8) | 16 (19.8) | 5 (20.8) | 11 (19.3) | NS |
| – Black | 624 (10.7) | 23 (28.4) | 7 (29.2) | 16 (28.1) | NS |
| – Other | 412 (7.1) | 3 (3.7) | 1 (4.2) | 2 (3.5) | NS |
| BMI (kg/m²) | | | |
| – Mean (SD) | NA | 30.9 (6.9) | 30.0 (6.6) | 31.2 (7.0) | NS |
| – Median (IQR) | NA | 29.6 (25.7–34.6) | 29.7 (23.8–34.4) | 29.6 (26.1–34.6) | NS |
| BMI categories (n (%); kg/m²) | | | |
| – <18.5 | 32 (0.5) | 0 (0) | 0 (0) | 0 (0) | NS |
| – 18.5 to ≤25 | 1468 (24.1) | 18 (22.2) | 8 (33.3) | 10 (17.5) | NS |
| – 25 to ≤30 | 2165 (35.6) | 24 (29.6) | 4 (16.7) | 20 (35.1) | NS |
| – 30 to ≤40 | 1970 (32.4) | 32 (39.5) | 11 (45.8) | 21 (36.8) | NS |
| – >40 | 447 (7.3) | 7 (8.6) | 1 (4.2) | 6 (10.5) | NS |
| Very severe co-morbidities | | | |
| – ≥1 co-morbidities (n (%)) | NA | 11 (13.6) | 5 (20.8) | 6 (10.5) | NS |
| – Mean (SD) | NA | 0.2 (0.4) | 0.3 (0.5) | 0.1 (0.4) | NS |
| – Median (IQR) | NA | 0 (0–0) | 0 (0–0) | 0 (0–0) | NS |
| APACHE II score | | | |
| – Mean (SD) | 15.3 (5.1) | 13.9 (3.7) | 14.9 (3.4) | 13.5 (3.8) | NS |
| – Median (IQR) | 15 (12–18) | 14 (11–17) | 14.5 (13–17) | 13 (11–17) | NS |
| PaO₂:FiO₂ ratio† | | | |
| – Mean (SD) | NA | 126.8 (55.2) | 133.1 (67.0) | 124.2 (50.0) | NS |
| – Median (IQR) | NA | 114 (81.8–159.0) | 119.1 (88.8–161.3) | 121.5 (72.7–179.7) | 119.1 (91.6–157.5) | NS |

*Data (patient characteristics of those receiving advanced respiratory support) taken from Intensive Care National Audit and Research Centre report 12 June 2020.†Derived from the lowest arterial blood gas measurement during the first 24 hours of care. ICNARC = Intensive Care National Audit and Research Centre; SD = standard deviation; IQR = interquartile range; NS = non-significant; BMI = body mass index; NA = not applicable; APACHE II = Acute Physiology and Chronic Health Evaluation II; PaO₂:FiO₂ = partial pressure of oxygen: fraction of inspired oxygen

### National Audit and Research Centre cohort, are presented in Table 1.

**Timing of tracheostomy**

The median (interquartile range) duration of invasive mechanical ventilation prior to tracheostomy was 16 (13–20) days. Fifty-seven tracheostomies (70.4 per cent) were performed on or after day 14. The (median (interquartile range)) levels of respiratory support required on the day of tracheostomy were as follows: PEEP of 8 (6–10) cmH₂O, fraction of inspired oxygen of 0.35 (0.3–0.4), and partial pressure of oxygen: fraction of inspired oxygen ratio of 204.9 (171.2–249.0). Sixty-two patients (93.9 per cent) required PEEP of 10 cmH₂O or less and fraction of inspired oxygen of 0.5 or less. The highest PEEP and fraction of inspired oxygen requirements were 14 cmH₂O and 0.55 respectively.

The median (interquartile range) CRP was 116 (50–192) mg/l. Nineteen patients (23.5 per cent) were receiving vasopressors, 29 (23.5 per cent) were receiving renal replacement therapy and 15 (18.5 per cent) were on extracorporeal membrane oxygenation. The results are summarised in Table 2.
performed at the bedside on the intensive care unit; this included all percutaneous procedures, and 2 hybrid procedures.

All of the procedures were successfully performed as per the pre-agreed technique and location. Three patients (3.7 per cent) required planned transfer to the operating theatre (one hybrid and two open procedures), two of which were because of patient morbid obesity (BMIs of 43 kg/m² and 61 kg/m²) with associated known difficult upper airways. The third patient was identified as having level VI calcific lymphadenopathy on computed tomography imaging; a level VI selective neck dissection was performed for both access and diagnostic purposes.

Overall, seven intra-operative complications (8.6 per cent) were recorded (Table 3). There was one episode (1.2 per cent) of intra-operative oxygen desaturations of less than 90 per cent on continuous monitoring. Post-operative complications are detailed in Table 3.

Overall, 25 patients (30.9 per cent) were receiving therapeutic and 50 (61.7 per cent) were receiving prophylactic anticoagulants around the time of tracheostomy. Bleeding (in 7.6 per cent) was documented as either oozing from the stoma or as the suctioning of fresh blood via tube. Three (60 per cent) of these patients were on continuous unfractionated heparin at the time of bleeding, with the remainder on prophylactic low molecular weight heparin. All cases were managed with suctioning, intravenous tranexamic acid and/or local injection

### Table 2. Timing, respiratory parameters, CRP and receipt of organ support on day of tracheostomy

| Parameter | Overall (n = 81) | Early tracheostomy (n = 24) | Late tracheostomy (n = 57) | Univariate analysis (p-values) |
|-----------|-----------------|-----------------------------|---------------------------|-------------------------------|
| Day of tracheostomy | | | | |
| – Mean (SD) | 16.3 (4.6) | 11.5 (1.8) | 19.9 (5.0) | |
| – Median (IQR) | 16 (13–20) | 12 (11–12) | 19 (16–22) | |
| CRP on day of tracheostomy (mg/l) | | | | |
| – Mean (SD) | 139.5 (102.6) | 142.5 (106.6) | 136 (100.8) | |
| – Median (IQR) | 116 (50–192) | 103 (77–197) | 122 (50–185) | NS |
| Receipt of organ support on day of tracheostomy (n %) | | | | |
| – Extracorporeal membrane oxygenation | 15 (18.5) | 7 (29.2) | 8 (14.0) | NS |
| – Renal replacement therapy | 29 (35.8) | 4 (16.7) | 25 (43.8) | 0.009 |
| – Vasopressors | 19 (23.5) | 5 (20.8) | 14 (24.6) | NS |
| – ≥1 organ support | 12 (14.8) | 3 (12.5) | 9 (15.8) | NS |
| PEEP on day of tracheostomy (cmH2O)* | | | | |
| – Mean (SD) | 7.8 (2.0) | 7.5 (1.6) | 8.0 (1.6) | |
| – Median (IQR) | 8 (6–10) | 8 (6–8) | 8 (6–10) | NS |
| – PEEP ≤10 (n %) | 74 (91.4) | 17 (100) | 45 (91.8) | NS |

### Table 3. Technique, and intra- and post-operative complications*

| Parameter | Value (n %) |
|-----------|-------------|
| Surgical technique | | |
| – Percutaneous | 76 (93.8) |
| – Open | 2 (2.5) |
| – Hybrid | 3 (3.7) |
| Intra-operative complications | | |
| – Overall | 7 (8.6) |
| – Misplacement | 2 (2.4) |
| – Bleeding† | 2 (2.4) |
| – Tracheal injury | 1 (1.2) |
| – ETT cuff puncture | 1 (1.2) |
| – Oxygen desaturations | 1 (1.2) |
| Post-operative complications | | |
| – Overall | 7 (8.6) |
| – Bleeding† | 5 (6.2) |
| – Suprastomal granulations | 2 (2.4) |

*Patients receiving extracorporeal membrane oxygenation on day of tracheostomy (n = 15) were excluded from analysis. CRP = C-reactive protein; SD = standard deviation; IQR = interquartile range; NS = non-significant; PEEP = positive end-expiratory pressure; FiO2 = fraction of inspired oxygen; PaO2/FiO2 = partial pressure of oxygen: fraction of inspired oxygen

†Both patients were on prophylactic low molecular weight heparin that was not omitted pre- or post-procedure; bleeding was managed with local direct pressure only. 
‡Three of the five patients (60 per cent) were on continuous unfractionated heparin infusions at the time of bleeding, and two of the five (40 per cent) were on prophylactic dose low molecular weight heparin; anticoagulant therapy was omitted on the day of post-operative bleeding. ETT = endotracheal tube
of lidocaine with adrenaline. No patients required blood transfusion or operative intervention. One patient (1.2 per cent) required microlaryngoscopy and debridement of suprastomal granulations to facilitate decannulation.

All operators and assistants wore powered air-purifying respirators or filtering facepiece code 3 (FFP3) masks and shield visors, along with a double-layer, fluid-repellent, disposable surgical gown and gloves. A team of five healthcare workers were present for every procedure, including two airway operators, two surgeons, and a runner/safety officer. There were 71 healthcare workers (average of 5.7 procedures each) involved in the tracheostomy teams. Of those surveyed, none developed Covid-19 symptoms within the relevant 14-day post-exposure window. The survey response rate was 81.7 per cent. Four healthcare workers reported having Covid-19 prior to undertaking the procedures.

**Outcomes and mortality**

The median (interquartile range) follow-up time was 32 (23–40) days post-tracheostomy insertion. Sixty-five patients (86.7 per cent) had been liberated from invasive mechanical ventilation, with a median (interquartile range) post-tracheostomy duration of ventilation of 12 (7–16) days. Moreover, 59 (86.7 per cent) of patients had been successfully decannulated and 44 (68.7 per cent) had been successfully discharged from hospital in a median (interquartile range) duration of 15 (12–21) days and 32 (22–37) days, respectively. Correlations between outcomes were analysed. We observed a strong correlation between stopping ventilation, decannulation (r = 0.734, p < 0.01) and hospital discharge (r = 0.454, p < 0.01). Detailed outcome data are presented in Table 4 and Figure 2. There were no significant differences between the early and late groups at baseline (Table 1), on the day of procedure (Table 2) or in post-tracheostomy outcomes (Table 4).

The overall mortality rate was 8.0 per cent (7 out of 81). Deaths occurred at a median (range) of 14 (5–40) days post-tracheostomy and 29 (17–50) days post-intubation. The cause of death was ventilator-dependant respiratory failure in all cases. There were no tracheostomy related deaths. For the subset receiving extracorporeal membrane oxygenation at the time of tracheostomy, the mortality rate was 26.7 per cent (4 out of 15); all of these patients were still receiving

### Table 4. Patient outcomes and mortality

| Parameter | Overall (n = 81) | Early tracheostomy (n = 24) | Late tracheostomy (n = 57) | Univariate analysis (p-values) |
|-----------|-----------------|-----------------------------|---------------------------|-----------------------------|
| Follow-up period |                   |                             |                           |                             |
| – Mean (SD) (days) | 32.6 (14.9) | 36.4 (16.2) | 31.1 (14.2) |                             |
| – Median (range) (days) | 32 (23–40) | 37 (24–42) | 31 (22–37) | NS                          |
| Sedation was stopped* |                   |                             |                           |                             |
| – Patients (n (%)) | 72 (90.0) | 19 (82.6) | 53 (93.0) | NS                          |
| – Mean (SD) (days) | 6.2 (6.6) | 5.6 (4.1) | 6.4 (7.4) |                             |
| – Median (IQR) (days) | 4 (2–9) | 5 (3–7.5) | 3.5 (2–9) | NS                          |
| Ventilation was stopped† |                   |                             |                           |                             |
| – Patients (n (%)) | 65 (86.7) | 18 (81.2) | 47 (88.7) | NS                          |
| – Mean (SD) (days) | 13.2 (8.3) | 14.3 (7.1) | 12.9 (8.7) |                             |
| – Median (IQR) (days) | 12 (7–16) | 13.5 (8–21) | 12 (7–16) | NS                          |
| ICU discharge‡ |                   |                             |                           |                             |
| – Patients (n (%)) | 62 (86.1) | 18 (81.2) | 44 (88.0) | NS                          |
| – Mean (SD) (days) | 18.2 (10.1) | 17.6 (8.2) | 18.5 (10.8) |                             |
| – Median (IQR) (days) | 16 (12–23) | 15 (11–25) | 17 (12–21) | NS                          |
| Decannulation** |                   |                             |                           |                             |
| – Patients (n (%)) | 59 (83.1) | 17 (80.9) | 42 (84.0) | NS                          |
| – Mean (SD) (days) | 21.4 (9.3) | 22.3 (8.0) | 21.0 (9.9) |                             |
| – Median (IQR) (days) | 19 (15–27) | 23 (15–27) | 18 (15–24) | NS                          |
| Hospital discharge§ |                   |                             |                           |                             |
| – Patients (n (%)) | 44 (68.7) | 14 (73.7) | 30 (66.7) | NS                          |
| – Mean (SD) (days) | 32.9 (11.5) | 38.4 (14.8) | 30.3 (8.8) |                             |
| – Median (IQR) (days) | 32 (25–39) | 37 (29–41) | 31 (24–37) | NS                          |
| Status of survival (n (%)) |                   |                             |                           |                             |
| – Alive | 74 (91.4) | 21 (87.5) | 53 (93.0) | NS                          |
| – Dead | 7 (8.6) | 3 (12.5) | 4 (7.0) | NS                          |

Missing data were a result of patients being transferred back to local units prior to outcomes being reached. *Data available for 80 of 81 patients (23 of 24 early and 57 of 57 late tracheostomy cases); † data available for 75 of 81 patients (22 of 24 early and 50 of 57 late tracheostomy cases); ‡ data available for 72 of 81 patients (22 of 24 early and 50 of 57 late tracheostomy cases); § data available for 64 of 81 patients (19 of 24 early and 45 of 57 late tracheostomy cases). SD = standard deviation; NS = non-significant; IQR = interquartile range; ICU = intensive care unit.
extracorporeal membrane oxygenation up until their time of death. The remaining cohort had a mortality rate of 4.5 per cent (3 out of 66).

**Discussion**

Despite a huge effort to produce guidelines to support decision-making and procedure for tracheostomy in Covid-19 patients, there still remains a paucity of published data on outcomes, complications and safety.

Our population was younger, and with a higher proportion of Black, Asian and minority ethnic groups, compared to the Intensive Care National Audit and Research Centre dataset.1 Our diverse local population may account for some of this variation. This study includes some of the most critically ill Covid-19 patients, with a significant proportion requiring the support of two or more organ systems, and a very high proportion receiving extracorporeal membrane oxygenation on the day of tracheostomy.

In this study, 29.6 per cent of patients underwent tracheostomy before the current recommended minimum time of 14 days. There was good adherence to departmental16 and British Laryngological Association7 guidelines with regard to levels of respiratory support, irrespective of timing of tracheostomy. We compared those who underwent tracheostomy before and after day 14, and observed no difference in outcomes. Furthermore, there was no difference in the baseline characteristics, or markers of disease severity on admission (Acute Physiology and Chronic Health Evaluation II score, and partial pressure of oxygen: fraction of inspired oxygen ratio) or on the day of tracheostomy (PEEP measurement, partial pressure of oxygen: fraction of inspired oxygen ratio, and CRP level). It therefore appears that timing may not be the single factor that should determine the decision to proceed with tracheostomy, and the broader clinical picture should be considered. Specifically, levels of respiratory support and other trends in markers of disease severity may play a significant role, and this warrants further study.

Overall complication rates were comparable to rates in existing published literature for non-coronavirus disease tracheostomy cases.5,19 Furthermore, rates of post-operative bleeding appear lower than for open techniques in Covid-19 patients,20 despite a high proportion of our cohort receiving therapeutic anticoagulant therapy. Misplacement rates appeared higher than previously published (1.5 per cent),5 which may be a result of small study size, but could reflect early attempts to avoid bronchoscope usage in order to minimise aerosol generation;15 our protocols were adopted to mitigate these risks.

Cuff puncture also presented a particular concern because of the risk of aerosol generation and the potential for prolonged loss of ventilation. This highlighted an important point, as endotracheal tube cuffs used on intensive care unit are longer than those commonly used in the operating theatre setting. In response, our anaesthetic colleagues developed a specific action card (Figure 3), utilising real-time ultrasound to minimise risk.

Intra-operative desaturations were reported as the most common complication in a multicentre interim report.20 By following our protocol to minimise periods of apnoea, and deferring tracheostomy until levels of ventilatory support were favourable, we were able to mitigate this risk in our study. This may also reflect patients in our study being in the later stages of recovery from illness by the time tracheostomy was performed.

Whilst there is still not consensus on which technique generates less aerosol,10,14,15 our standards of personal protective equipment (including powered air-purifying respirators) currently appear safe, with no identified healthcare worker transmission. The response rate in our follow-up survey of symptoms in this study may limit the accuracy of our findings; however, its results are reflective of other reports of tracheostomy in Covid-19.11,20,21

The obvious value of our bedside team-based approach has been to optimise resource utilisation during hugely challenging times. Moreover, the need to transfer patients to the operating
Fig. 3. Anaesthetic action card. COVID-19 = coronavirus disease 2019
The Journal of Laryngology & Otology 969

disease-specific factors that may influence the clinical course
the duration of weaning and rehabilitation; research into
cannot account for the levels of variation observed in
comes to date. We observed that most patients were success-
variable data on associated post-tracheostomy outcomes, and
– have shown mortality rates in the region of 35.3
Covid-19 patients. Early case series of Covid-19 patients
matic approach was taken given the current lack of literature
association extracorporeal membrane oxygenation in
– consideration of tracheostomy is
– receiving mechanical ventilation at the time of reporting and
however, a small number of patients in this cohort were still
– the final mortality rate may eventually be higher.
Mortality rates were higher amongst patients receiving
extracorporal membrane oxygenation at the time of
tracheostomy, and this may call into question the value of
tracheostomy patients with Covid-19 in this or other pub-
Conclusions on the overall positive or negative impact for
tracheostomy patients with Covid-19 in this or other pub-
Lancet 2020;395:1763–70
3 Wang R, Pan C, Wang X, Xu F, Jiang S, Li M. The impact of tracheostomy
timing in critically ill patients undergoing mechanical ventilation: a
meta-analysis of randomized controlled clinical trials with trial sequential
analysis. Hear Lung 2019;48:46–54
4 Adly A, Youssef TA, El-Begermy MM, Yonnis HM. Timing of tracheos-
tomy in patients with prolonged endotracheal intubation: a systematic review.
Eur Arch Otorhinolaryngol 2018;275:679–90
5 Young D, Harrison DA, Cuthbertson BH, Rowan K. Effect of early vs late
tracheostomy placement on survival in patients receiving mechanical venti-
lation: the TracMan randomized trial. JAMA 2013;309:2212–9
6 ENT-UK. COVID-19 Tracheostomy Guidance. In: https://www.entuk.org/
covid-19-tracheostomy-guidance-t-jacob-et-al [20 June 2020]
7 British Laryngological Association. Tracheostomy Guideline - COVID-19.
In: https://www.britishlaryngological.org/news/tracheostomy-guideline-covid-
19 [20 June 2020]
8 McGrath BA, Ashby N, Birchall M, Dean P, Doherty C, Ferguson K et al.
Multidisciplinary guidance for safe tracheostomy care during the
COVID-19 pandemic; the NHS National Patient Safety Improvement
Programme (NatPatSIP). Anaesthesia 2020. Epub 2020 May 12
9 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and throm-
bosis in patients with COVID-19. Lancet Haematol 2020;7:e438–40
10 Tay JK, Khoo ML, Loh WS. Surgical considerations for tracheostomy
during the COVID-19 pandemic: lessons learned from the severe
acute respiratory syndrome outbreak. JAMA Otolaryngol Head Neck Surg
2020;146:517–18
11 Chao TN, Harbison SP, Braslows BM, Hutchinson CT, Rajasekaran K, Go
BC et al. Outcomes after tracheostomy in COVID-19 patients. Ann Surg
2020;272:e181–6
12 Turri-Zanoni M, Rattaglia P, Czaczkes C, Pelosi P, Castellnuvo P, Cabrini
L. Elective tracheostomy during mechanical ventilation in patients affected
by COVID-19: preliminary case series from Lombardy, Italy. Otolaryngol
Head Neck Surg 2020;163:375–7
13 Riestra-Ayora J, Yanes-Diaz J, Penuelas O, Molina-Quiros C, Sanz-
Fernández R, Martin-Sanz E. Safety and prognosis in percutaneous vs

References
1 ICNARC report on COVID-19 in critical care. ICNARC COVID-19 Study
Case Mix Programme Database 2020. In: https://www.icnarc.org/OurAudit/ Audits/Cmp/Reports [22 June 2020]
2 Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough
EM et al. Epidemiology, clinical course, and outcomes of critically ill adults
with COVID-19 in New York City: a prospective cohort study. Lancet
2020;395:1763–70
3 Wang R, Pan C, Wang X, Xu F, Jiang S, Li M. The impact of tracheostomy
timing in critically ill patients undergoing mechanical ventilation: a
meta-analysis of randomized controlled clinical trials with trial sequential
analysis. Hear Lung 2019;48:46–54
4 Adly A, Youssef TA, El-Begermy MM, Yonnis HM. Timing of tracheostomy
in patients with prolonged endotracheal intubation: a systematic review.
Eur Arch Otorhinolaryngol 2018;275:679–90
5 Young D, Harrison DA, Cuthbertson BH, Rowan K. Effect of early vs late
tracheostomy placement on survival in patients receiving mechanical venti-
lation: the TracMan randomized trial. JAMA 2013;309:2212–9
6 ENT-UK. COVID-19 Tracheostomy Guidance. In: https://www.entuk.org/
covid-19-tracheostomy-guidance-t-jacob-et-al [20 June 2020]
7 British Laryngological Association. Tracheostomy Guideline - COVID-19.
In: https://www.britishlaryngological.org/news/tracheostomy-guideline-covid-
19 [20 June 2020]
8 McGrath BA, Ashby N, Birchall M, Dean P, Doherty C, Ferguson K et al.
Multidisciplinary guidance for safe tracheostomy care during the
COVID-19 pandemic; the NHS National Patient Safety Improvement
Programme (NatPatSIP). Anaesthesia 2020. Epub 2020 May 12
9 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and throm-
bosis in patients with COVID-19. Lancet Haematol 2020;7:e438–40
10 Tay JK, Khoo ML, Loh WS. Surgical considerations for tracheostomy
during the COVID-19 pandemic: lessons learned from the severe
acute respiratory syndrome outbreak. JAMA Otolaryngol Head Neck Surg
2020;146:517–18
11 Chao TN, Harbison SP, Braslows BM, Hutchinson CT, Rajasekaran K, Go
BC et al. Outcomes after tracheostomy in COVID-19 patients. Ann Surg
2020;272:e181–6
12 Turri-Zanoni M, Rattaglia P, Czaczkes C, Pelosi P, Castellnuvo P, Cabrini
L. Elective tracheostomy during mechanical ventilation in patients affected
by COVID-19: preliminary case series from Lombardy, Italy. Otolaryngol
Head Neck Surg 2020;163:375–7
13 Riestra-Ayora J, Yanes-Diaz J, Penuelas O, Molina-Quiros C, Sanz-
Fernández R, Martin-Sanz E. Safety and prognosis in percutaneous vs

The mortality rate in this study is lower than the 31.5 per
cent 30-day mortality reported in a large trial of critically ill
patients who underwent prolonged mechanical ventilation,5
however, a small number of patients in this cohort were still
receiving mechanical ventilation at the time of reporting and so
the final mortality rate may eventually be higher.
Mortality rates were higher amongst patients receiving
extracorporeal membrane oxygenation at the time of
tracheostomy, and this may call into question the value of
performing tracheostomy on this subset of patients. In
non-coronavirus disease populations receiving extracorporeal
membrane oxygenation, consideration of tracheostomy is
recommended for patients deemed to be on a trajectory to
recovery, as it has the same perceived benefits of reduced
sedation requirements and a lower incidence of ventilator-
associated pneumonia.12–24 In this study, patients receiving
extracorporeal membrane oxygenation were selected for
tracheostomy according to the same principles as non-
extracorporeal membrane oxygenation patients. This
pragmatic approach was taken given the current lack of literature
surrounding extracorporeal membrane oxygenation in
Covid-19 patients. Early case series of Covid-19 patients
have shown mortality rates in the region of 35.3–44 per
cent for this group,25,26 but the specific role of tracheostomy is
not yet fully understood.
A key limitation of this study is that it describes a single-
centre experience only, with a relatively small sample size, thus
limiting the generalisability of our findings. However, it
does represent a prospective study where patients were treated
in accordance with current national guidance, and where pro-
cedures were performed according to a defined protocol.
Given the current variation in practice and outcomes,
there is an urgent need for multicentre analysis, to better
understand the optimal timing, indications and outcomes.
Although tracheostomy has well-documented benefits for
non-coronavirus disease patients requiring prolonged
respiratory weaning,3,4 it is not possible to draw any firm
conclusions on the overall positive or negative impact for
tracheostomy patients with Covid-19 in this or other pub-
lished studies.1,13,15,20,21,27,28 Prospective, randomised clinical
trials are required to further address this for further waves of
the Covid-19 pandemic.

Acknowledgements. A special thanks to all of our ENT, head and neck,
tensive care, and anaesthetic colleagues who have supported the develop-
ment and delivery of this service. Thank you to Paul Greig who helped to
develop the percutaneous tracheostomy anaesthetic action card and graphics.

Competing interests. None declared

• The coronavirus disease 2019 (Covid-19) pandemic has placed
unprecedented demand on critical care for invasive mechanical
ventilation
• A significant number of patients may benefit from tracheostomy, but
evidence on optimal timing, technique and efficacy is lacking
• In 81 patients, percutaneous tracheostomy complications were
comparable to non-Covid-19 populations, and lower than for open
tracheostomy in Covid-19 patients
• There were no reported episodes of healthcare worker transmission and
no tracheostomy related deaths
• Of patients, 86.7 per cent were liberated from invasive mechanical
ventilation in a median (interquartile range) of 12 (7–16) days
• An airway management algorithm for percutaneous tracheostomy
utilising ultrasound and bronchoscopy is presented

https://doi.org/10.1017/S0022215120002303 Published online by Cambridge University Press
surgical tracheostomy in 27 patients with COVID-19. *Otolaryngol Head Neck Surg* 2020;163:462–4.

14 Schultz P, Morvan JB, Fakhry N, Morinière S, Vergez S, Lacroix C et al. French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic. *Eur Ann Otorhinolaryngol Head Neck Dis* 2020;137:167–9

15 Miles BA, Schiff B, Ganly I, Ow T, Cohen E, Genden E et al. Tracheostomy during SARS-CoV-2 pandemic: recommendations from the New York Head and Neck Society. *Head Neck* 2020;42:1282–90

16 Takhar A, Walker A, Tricklenbank S, Wyncol D, Hart N, Jacob T et al. Recommendation of a practical guideline for safe tracheostomy during the COVID-19 pandemic. *Eur Arch Otorhinolaryngol* 2020;277:2173–84

17 Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H et al. Prognostic value of C-reactive protein in patients with COVID-19. *Clin Infect Dis* 2020. Epub 2020 May 23

18 Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. *J Med Virol* 2020;92:856–62

19 Lipton G, Stewart M, McDermid R, Docking R, Urquhart C, Morrison M et al. Multispecialty tracheostomy experience. *Ann R Coll Surg Engl* 2020;102:343–7

20 COVIDtrach; the outcomes of mechanically ventilated COVID-19 patients undergoing tracheostomy in the UK. In: [https://www.entuk.org/sites/default/files/COVIDTrach-InterimReport%2C22May2020.pdf](https://www.entuk.org/sites/default/files/COVIDTrach-InterimReport%2C22May2020.pdf) [23 October 2020]

21 Angel L, Kon ZN, Chang SH, Rafeq S, Shekar SP, Mitzman B et al. Novel percutaneous tracheostomy for critically ill patients with COVID-19. *Ann Thorac Surg* 2020;110:1006–11

22 Dimopoulos S, Joyce H, Camporota L, Glover G, Ioannou N, Langrish CJ et al. Safety of percutaneous dilatational tracheostomy during veno-venous extracorporeal membrane oxygenation support in adults with severe respiratory failure. *Crit Care Med* 2019;47:e81–8

23 Brogan T, Lequier L, Lorusso R, MacLaren R, Peek G, eds. *Extracorporeal Life Support: The ELSO Red Book*, 5th edn. Ann Arbor: ELSO, 2017

24 Grewal J, Sutt AL, Cornmell G, Shekar K, Fraser J. Safety and putative benefits of tracheostomy tube placement in patients on extracorporeal membrane oxygenation: a single-center experience. *J Intensive Care Med* 2020;35:1153–61

25 Falcoz PE, Monnier A, Puyraveau M, Perrier S, Ludes PO, Olland A et al. Extracorporeal membrane oxygenation for critically ill patients with COVID-19 – related acute respiratory distress syndrome: worth the effort? *Am J Respir Crit Care Med* 2020;202:460–3

26 Hu HT, Xu S, Wang J, Rao X. Respiratory support in severely or critically ill ICU patients with COVID-19 in Wuhan, China. *Curr Med Sci* 2020;40:636–41

27 Ferri E, Boscolo Nata F, Pedruzzi B, Campolieti G, Scotto di Clemente F, Baratto F et al. Indications and timing for tracheostomy in patients with SARS-CoV2-related. *Eur Arch Otorhinolaryngol* 2020;277:2403–4

28 Mattioli F, Fermi M, Girotto M, Molteni G, Sgarbi N, Bertellini E et al. Tracheostomy in the COVID-19 pandemic. *Eur Arch Otorhinolaryngol* 2020;277:2133–5